...
首页> 外文期刊>Brain research >Oligodendrocyte progenitor programming and reprogramming: Toward myelin regeneration
【24h】

Oligodendrocyte progenitor programming and reprogramming: Toward myelin regeneration

机译:少突胶质祖细胞编程和重编程:髓鞘再生

获取原文
获取原文并翻译 | 示例
           

摘要

Demyelinating diseases such as multiple sclerosis (MS) are among the most disabling and cost intensive neurological disorders. The loss of myelin in the central nervous system, produced by oligodendrocytes (OLs), impairs saltatory nerve conduction, leading to motor and cognitive deficits. Immunosuppression therapy has a limited efficacy in MS patients, arguing for a paradigm shift to strategies that target OL lineage cells to achieve myelin repair. The inhibitory microenvironment in MS lesions abrogates the expansion and differentiation of resident OL precursor cells (OPCs) into mature myelin-forming OLs. Recent studies indicate that OPCs display a highly plastic ability to differentiate into alternative cell lineages under certain circumstances. Thus, understanding the mechanisms that maintain and control OPC fate and differentiation into mature OLs in a hostile, non-permissive lesion environment may open new opportunities for regenerative therapies. In this review, we will focus on 1) the plasticity of OPCs in terms of their developmental origins, distribution, and differentiation potentials in the normal and injured brain; 2) recent discoveries of extrinsic and intrinsic factors and small molecule compounds that control OPC specification and differentiation; and 3) therapeutic potential for motivation of neural progenitor cells and reprogramming of differentiated cells into OPCs and their likely impacts on remyelination. OL-based therapies through activating regenerative potentials of OPCs or cell replacement offer exciting opportunities for innovative strategies to promote remyelination and neuroprotection in devastating demyelinating diseases like MS. This article is part of a Special Issue entitled SI:NG2-glia(Invited only). (C) 2015 Elsevier B.V. All rights reserved.
机译:多发性硬化症(MS)等脱髓鞘疾病是最致残,成本最高的神经系统疾病之一。少突胶质细胞(OL)导致中枢神经系统中髓磷脂的丢失,损害了盐神经的传导,导致运动和认知功能障碍。免疫抑制疗法在MS患者中的疗效有限,主张将范式转移到靶向OL谱系细胞以实现髓磷脂修复的策略。 MS病变中的抑制性微环境消除了驻留的OL前体细胞(OPC)向成熟的形成髓鞘的OL的扩展和分化。最近的研究表明,OPC在某些情况下具有高度的可塑性,可以分化为其他细胞谱系。因此,了解在敌对的,非允许的病变环境中维持和控制OPC命运以及分化为成熟OL的机制可能为再生疗法打开新的机会。在这篇综述中,我们将着重于以下方面:1)OPC在正常和受伤的大脑中的起源,分布和分化潜能方面的可塑性; 2)最近发现的外在因素和内在因素以及控制OPC规格和分化的小分子化合物; 3)刺激神经祖细胞和将分化后的细胞重编程为OPC的治疗潜力及其对髓鞘再生的影响。通过激活OPC的再生潜能或细胞替代的基于OL的疗法为促进毁灭性脱髓鞘疾病(如MS)中的髓鞘再生和神经保护的创新策略提供了令人兴奋的机会。本文是名为SI:NG2-glia(仅受邀)的特刊的一部分。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号